EndoStim develops a minimally-invasive implantable device that delivers low-energy personalized neurostimulation to restore lower esophageal sphincter (LES) function and provide long-term reflux control. The therapy directly targets a weak or dysfunctional LES, often the underlying cause of reflux. The EndoStim system is CE marked for patients with GERD of six months or longer and is available in multiple countries across Europe, Latin America and Asia Pacific. The device is not approved for sale in the United States. EndoStim is based in St. Louis, Missouri and Nijmegen, The Netherlands. The company completed a $25m Series D financing and plans to use the funds to expand commercialization outside the U.S., run a randomized sham-controlled pivotal trial in the U.S., and develop next-generation devices. EndoStim is a St. Louis-based medical device company developing minimally-invasive interventional therapies to treat gastrointestinal and urological neuro-muscular disorders. Its new treatment targets sphincter-related disorders such as gastroesophageal reflux disease (GERD) and urinary urge incontinence using neurostimulation to restore physiological function. The company is advancing clinical trials for these therapies. Proceeds from the financing will be used to continue those trials and to pursue CE Mark and FDA approvals. The company recently expanded its board with investors and industry representatives. The firm raised new capital via a Series B equity financing to support these near-term regulatory and clinical milestones.

Total raised

$31M

Funding rounds

2

Latest round

Series D

Latest activity

May 2016